M K Proteins promoters confirm zero share encumbrances for FY26

1 min read     Updated on 16 Jun 2026, 04:59 AM
scanx
Reviewed by
Jubin VScanX News Team
AI Summary

M K Proteins disclosed that its promoter group held no encumbered shares as of March 31, 2026. Declarations filed under SEBI regulations confirm that no shares were pledged during FY26. The promoter group entities collectively hold 4.86 crore equity shares.

powered bylight_fuzz_icon
43111758

*this image is generated using AI for illustrative purposes only.

M K Proteins disclosed that its promoter group held no encumbered shares as of March 31, 2026, confirming compliance with SEBI regulations for the financial year ended March 31, 2026. The declarations submitted to the stock exchanges verify that the promoters have not pledged any shares directly or indirectly during the period. This status reduces risk for shareholders by indicating that the promoter's stake is free from liens, which can otherwise signal financial stress or impact corporate control.

The company submitted the disclosures under Regulation 31(4) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. The filing includes confirmations from individual promoters and promoter group entities regarding their shareholding status. Parmod Kumar, Managing Director & Promoter, confirmed on behalf of the group that the number of encumbered or pledged shares was NIL as of the financial year-end.

Promoter Group Holdings

The declarations detail the specific shareholding of each entity within the promoter group. All entities confirmed that they have not created any encumbrance over their respective holdings during FY26.

Entity Shares Held as on 31 March 2026 Encumbrance Status
Shib Charan Dass Industries Private Limited 1,60,20,000 No encumbrance
Kamla Finvest Private Limited 2,10,60,000 No encumbrance
Shree Ganesh Fats Private Limited 1,15,20,000 No encumbrance

The combined shareholding of these promoter group entities totals 4,86,00,000 equity shares. The confirmations were addressed to the Audit Committee of M K Proteins , the National Stock Exchange of India Limited, and BSE Limited. The letters were signed by the authorized directors of the respective entities on April 6, 2026.

Historical Stock Returns for MK Proteins

1 Day5 Days1 Month6 Months1 Year5 Years
-0.60%+0.41%-3.52%-17.67%-41.47%+431.18%

Will M K Proteins utilize its unencumbered promoter status to pursue acquisitions or capacity expansion in FY27?

How might this clean shareholding structure influence institutional investor confidence and stock valuations?

Does the company plan to maintain a zero-pledge policy permanently, or could future capital requirements change this stance?

M K Proteins FY26 net profit falls 18.7% to ₹682.90 lakh

1 min read     Updated on 02 Jun 2026, 06:16 AM
scanx
Reviewed by
Shriram SScanX News Team
AI Summary

M K Proteins Limited reported an 18.7% decline in net profit to ₹682.90 lakh for FY26, despite a 43% rise in revenue to ₹38287.52 lakh. The company published its audited financial results in newspapers on June 01, 2026.

powered bylight_fuzz_icon
41609124

*this image is generated using AI for illustrative purposes only.

M K Proteins Limited reported an 18.7% decline in net profit to ₹682.90 lakh for the financial year ended March 31, 2026, despite a 43% increase in revenue from operations to ₹38287.52 lakh. The company’s board approved the audited standalone financial results for the quarter and year ended March 31, 2026, during a meeting held on May 29, 2026. The statutory auditors, M/s Subhash Sajal and Associates, issued an unmodified opinion on the audited standalone financial results.

For the quarter ended March 31, 2026, the company recorded a profit of ₹113.83 lakh, a decrease from ₹279.61 lakh in the corresponding period of the previous year. Revenue from operations for the quarter stood at ₹14594.06 lakh, compared to ₹13720.41 lakh in the year-ago quarter. Pursuant to Regulation 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the company published the audited financial results in the Financial Express and Jansatta on June 01, 2026.

Financial Performance

The annual results show that while total income grew, expenditure increased significantly, impacting the bottom line. Total expenditure for FY26 rose to ₹37374.60 lakh from ₹25673.16 lakh in FY25. The cost of materials consumed was ₹28648.84 lakh, and purchases of stock-in-trade amounted to ₹7369.24 lakh.

Key Financial Metrics (FY26 vs FY25)

Metric FY26 (₹ in Lakhs) FY25 (₹ in Lakhs)
Revenue from Operations 38287.52 26770.60
Total Expenditure 37374.60 25673.16
Profit Before Tax 938.86 1145.10
Net Profit 682.90 839.74
Basic EPS 0.18 0.22

Auditor Appointments

The board re-appointed M/s. K. K. Sinha & Associates as Cost Auditors for the financial year 2026-27. Additionally, M/s. Jayant Bansal & Co., Chartered Accountants, were re-appointed as Internal Auditors for FY27. The company confirmed there were no outstanding defaults on loans and debt securities as of March 31, 2026.

Borrowings and Ratings

Outstanding borrowings as of March 31, 2026, stood at ₹36.19 crore, down from ₹37.75 crore in the previous year. The company holds an 'A' rating for both long-term and short-term bank facilities from CRISIL. M K Proteins confirmed it is not classified as a Large Corporate under SEBI regulations.

Historical Stock Returns for MK Proteins

1 Day5 Days1 Month6 Months1 Year5 Years
-0.60%+0.41%-3.52%-17.67%-41.47%+431.18%

What specific factors drove the 45% surge in expenditure, particularly regarding material costs, and will these pressures persist?

How does the company plan to restore profit margins given the widening gap between revenue growth and net profit?

Will the significant revenue growth be sustained in FY27, or was it driven by one-time market factors?

More News on MK Proteins

1 Year Returns:-41.47%